Aerpio Pharmaceuticals, a biopharmaceutical company, completed the merger with Aadi Bioscience, a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers. The PIPE investments was led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital Partners, BVF Partners, Vivo Capital; Alta Bioequities, Rock Springs Capital, RTW Investments, Acorn Bioventures and Serrado Capital. Financial terms were not disclosed. “Today’s news represents an important inflection point for Aadi and the development of FYARRO. The completion of the merger, and now becoming a public entity, allows us to take the next step toward commercialization of our pipeline," Neil Desai, Aadi Bioscience CEO.